1-3 of 3
Hui Tang
Close
Sort by
Journal Articles

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Clinical Trials & Observations
Thomas E. Witzig, Hui Tang, Ivana N. M. Micallef, Stephen M. Ansell, Brian K. Link, David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Carrie A. Thompson, Cristine Allmer, Matthew J. Maurer, Mamta Gupta, George Weiner, Ray Hohl, Paul J. Kurtin, Husheng Ding, David Loegering, Paula Schneider, Kevin Peterson, Thomas M. Habermann, Scott H. Kaufmann
Journal: Blood
Blood (2011) 118 (18): 4882–4889.
https://doi.org/10.1182/blood-2011-02-334904
Published: 2011
Journal Articles

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

Stephen M Ansell, MD, PhD, Hui Tang, PhD, Grzegorz S. Nowakowski, MD, Daniel Nikcevich, MD, PhD, Garth D Nelson, Charles Erlichman, MD, Thomas E Witzig, MD, North Central Cancer Treatment Group
Journal: Blood
Blood (2010) 116 (21): 2862.
https://doi.org/10.1182/blood.V116.21.2862.2862
Published: 2010
Journal Articles

A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

Stephen M Ansell, Hui Tang, BS, MA, PhD, Paul Kurtin, Patricia Koenig, David J Inwards, Keith Shah, Thomas E Witzig, MD
Journal: Blood
Blood (2009) 114 (22): 1665.
https://doi.org/10.1182/blood.V114.22.1665.1665
Published: 2009